The Breakout Breakdown
A mid-session breakout screen printed 28 hits out of 80 names. These 10 cleared a “strong” trend filter and closed above a rising zero-lag EMA. They are not one trade. They are four different tapes sharing a scanner label.
Disclaimer. This is research and market commentary, not investment advice, a recommendation, or an offer to buy or sell any security. Nothing here is personalized to your situation. Prices are approximate September 2, 2026 closing / late-session references. Levels, percentage returns, and probabilities are scenario estimates, not forecasts and not backtested statistics. Markets gap. Stops are not guaranteed fills. You can lose some or all of the capital you put at risk. Do your own work. Past movement is not a promise of future movement.
Affiliates, issuers, or platforms mentioned are not endorsing this post. No compensation was received for naming these stocks.
How to read the scanner
The header was breakout hits = 28/80 · seeds + Finviz · 2026-09-02. That means a custom universe, not the whole market. Healthcare is overweight because the seed list is overweight. Score is a relative-strength / trend composite. DIST is how far price had already run above the zero-lag EMA at snapshot time. DIST tells you how late you are. It does not tell you whether the thesis is any good.
| Column | What it actually means |
|---|---|
| Score 100 | Cleanest relative-strength + volume + trend combo in this batch. |
| Type: strong | Trend filter passed. Not a mean-reversion ping. |
| DIST +10.9% | Already an extension day. Buying GTLB there is a different trade than buying SDGR at +1.7%. |
| ZLEMA | Zero-lag exponential average. First pullback toward it is usually the higher-quality entry. |
The scanner snapshot was mid-session. By the close several names had extended further, especially FMC, OABI, ALNY, and ATRC. Use closing context for risk. Use the snapshot only to understand why the name printed.
The four tapes inside one list
- Earnings and spin-off resets: GTLB, MMED.
- Medtech / biotech event momentum: ATRC, ALNY, EXEL, OABI, NVAX, SDGR.
- Distressed balance-sheet bounce: FMC.
- Cash-return / activist special: ETD.
If you buy the whole screen as one book, you are mostly long healthcare beta plus one software gap and one furniture event. That is a factor bet, not a diversified breakout portfolio.
Name-by-name
1. GTLB — GitLab
This is the cleanest “why today” name. GitLab reported revenue of about $286 million, up 21% year over year, versus a $273 million-ish consensus. Adjusted EPS was $0.24 versus $0.18. Billings rose about 24%. Net ARR grew 42%. Dollar-based net retention was 117%. First orders roughly doubled to about 1,700. Deals of $500,000-plus jumped more than 150%. Fiscal 2027 guidance moved to $1.129–$1.133 billion in revenue and $0.85–$0.87 in adjusted EPS.
The call was not only beat-and-raise. Flex and AI were the point. Management said more than 130 customers committed over $20 million to Flex in six weeks and that paid consumption run-rate moved above $40 million. Ultimate reached 59% of ARR. Sales capacity was up about 30% year over year with productivity up about 10%.
How to treat it. This is a regime-change print if Flex is real. GitLab has been a good product with uneven go-to-market. Linearity, large-deal mix, and AI demand showed up in the same quarter. Street targets were still clustered in the mid-$50s while the stock was ripping, which means the Street is digesting, not crowning it. The first hold of the ZLEMA / gap zone is a better trade than paying the extension. Next-quarter bookings flattening, Flex remaining a curiosity, or net retention rolling over kills the thesis.
2. MMED — MiniMed Group
Medtronic still owns roughly 90% pending a tax-free distribution, which is why the float can trend violently after a clean independent print. Market cap is mid-single-digit billions. The stock has already come a long way off the post-spin lows.
Fiscal Q1 2027 sales were $843 million, up 17% reported and 16% organic. U.S. sales grew 13%. International organic growth was about 17%. U.S. new pumps sold rose more than 20% on MiniMed Flex and new sensors. Management raised fiscal 2027 organic growth to about 10.5% from about 10% and kept adjusted EBITDA margin guidance around 16%. The pipeline moved ahead of schedule: MiniMed Fit FDA submission, Flex CE Mark, Vivera fully closed-loop pivotal enrollment complete, and an IDE for a next-generation extended-wear sensor.
How to treat it. Classic spin-off plus first independent beat. The bull case is Flex plus sensors plus closed loop into 2027. The bear case is a number-two or number-three pump franchise with still-thin standalone margins and a parent distribution overhang. September 2 was already day two of the earnings gap. That is why the preferred entry is the gap shelf, not the high tick. U.S. pump growth fading after launch noise, or a Medtronic distribution supply dump, is the kill switch.
3. ATRC — AtriCure
Surgical AFib, left-atrial-appendage management, and post-op pain. Mid-teens growth and a business that is just crossing into real profitability. Fiscal 2026 revenue guidance sits near $602–$610 million. Adjusted EBITDA was raised toward the mid-to-high $80 millions after the second quarter.
Two pipeline items matter more than the daily print. BoxX-NoAF, a 960-patient trial of prophylactic ablation plus LAA exclusion to prevent post-op AFib, is enrolling about a year early, with completion targeted around year-end 2026. Analysts lifted targets into the $60–$64 area on the trial path and STS quality-metric adoption. Separately, the company treated first patients in Australia with a dual pulsed-field plus radiofrequency clamp platform. Box-lesion ablation time was reported under 60 seconds. That platform is not approved anywhere yet.
How to treat it. Highest-quality medtech compounder on the list. This is not a one-headline spike. It is a year of product mix plus a TAM-expanding trial pulling forward. You are paying a growth-medtech multiple, not a distressed stub. A third-quarter air pocket or sloppy BoxX enrollment quality is the invalidation.
4. ALNY — Alnylam
Two-act setup. On July 30 the company printed about $1.2 billion in product sales, up 74% year over year, with AMVUTTRA clearing $1 billion in a single quarter. Then it cut TTR guidance by about $200 million because second-line demand normalized after launch pull-forward. The stock had a crash day. Law-firm letters followed.
Last week and this week repaired the narrative. ESC 2026 data framed AMVUTTRA TTR knockdown and HELIOS-B subgroups against competing antisense data. Several desks treated the July break as oversold versus a franchise that is still growing: full-year product guidance remains $4.7–$5.1 billion, implying very large TTR growth even after the cut.
How to treat it. This is a washout bounce, not a fresh all-time-high breakout. The ZLEMA distance looks small because the average itself got crushed. Size it like a high-beta large-cap biotech. The July low zone is the hard risk line. A second guidance cut would say the July print was the start of a cluster, not a one-off growth-rate debate.
5. OABI — OmniAb
Asset-light antibody and ion-channel discovery platform. August 6 brought a better quarter and a higher 2026 revenue range. August 17 brought the real spark: a global ion-channel collaboration with Eli Lilly. Upfront was undisclosed. Milestones can reach $370 million plus royalties. Cash guidance moved up with the deal.
September 2 looked like continuation and options activity, not a new press release. From roughly $2 to $5 in a month, the easy work is done. A $700 million-plus market cap on still-small revenue is a partnership premium. That premium holds if more Lilly-class deals show up. It compresses fast if this was the only print.
How to treat it. Best percentage upside on a pullback, lowest probability if you chase $5. No follow-on business development, a cash-guide slip, or a close back under about $4 ends the momentum thesis.
6. EXEL — Exelixis
Cabozantinib is the engine. Second-quarter total revenue was about $629 million. U.S. cabo net product revenue was $573 million, up 10%. The global franchise, including partners, was $806 million, up 13%. Non-GAAP EPS was $0.91. Management still cut full-year 2026 total revenue to $2.50–$2.55 billion on a slower neuroendocrine ramp — and the stock made highs anyway. That is the tell. The company also bought back more than $300 million of stock in the quarter and finished a $750 million authorization.
The next binary is zanzalintinib plus atezolizumab in previously treated metastatic colorectal cancer. PDUFA is December 3, 2026. Survival data have been directionally positive without being a clean statistical slam. The longer-term debate is the cabo patent cliff into the early 2030s.
How to treat it. Best defensive biotech cash-flow name on the list. Upside from an all-time high is about zanza and cabo durability, not a new multiple. Add weakness in the mid-50s. Do not hero-call the high tick.
7. NVAX — Novavax
What is real: late-August authorizations for the 2026–27 XFG-adapted Nuvaxovid in the United States, Europe, and Japan. Second-quarter total revenue was only $57 million because old milestone comps rolled off, but product and adjuvant sales were much stronger and 2026 adjusted revenue guidance moved to $235–$275 million excluding Sanofi royalties. The company is no longer trying to be a full-stack COVID commercial engine. Sanofi sells the shot. Novavax keeps a royalty and Matrix-M economics and is aiming for non-GAAP profitability around 2028.
What is noise: midweek oncology / Matrix-M speculation that was not a company announcement.
How to treat it. Asymmetric only if the royalty stack can support a multi-billion-dollar company on a lean cost base. As a breakout, it was one of the least extended biotech names on the screen. History says it can give the month back on a quiet policy week.
8. FMC — FMC Corporation
The business is still shrinking. Second-quarter sales were $867 million, down 17%. Full-year sales guidance is $3.50–$3.70 billion. Adjusted EBITDA guidance is $620–$680 million. Grower margins, diamide partner destocking, and the India exit all weigh on the P&L. Debt has been the actual story.
Why it can still trend: Tessenderlo agreed to buy about 20% of the company at $13.30 for $400 million. Corteva paid $200 million upfront for rimisoxafen access. The India commercial business was slated for a $252 million sale. A Newark sale-leaseback added more cash. Management’s target has been about $1 billion of debt paydown while new active ingredients work through regulators.
How to treat it. A technical bounce into the deal reference price. Not a quality compounder. If the Tessenderlo capital closes, $13–$15 is a magnet. If ag pricing stays ugly into 2027, it is a value trap with a Belgian partner. Another guide cut or a close back through $11 breaks the bounce.
9. SDGR — Schrödinger
Second-quarter annual contract value was $29.6 million, up 27%, and $208 million on a trailing four-quarter basis. Total revenue was mixed because software is shifting to a hosted model. Drug-discovery revenue included a collaboration milestone tied to the Ajax / Lilly situation. Full-year ACV guidance is $218–$228 million. Discovery revenue guidance was raised to $65–$75 million. Bunsen, the agentic AI co-scientist, plus a Bristol Myers Squibb software agreement is the narrative hook.
How to treat it. Least extended name. Also the least urgent. This is a platform that actually invoices pharma, not a breakout you need to act on the same night. Consensus fair-value talk clusters near the current price.
10. ETD — Ethan Allen
The tape is about capital return, not sofas. Fiscal 2026 sales were $579.5 million, down about 6%. The company is debt-free with a large cash pile. The board declared a $3.00 special dividend, roughly $76 million in total, to holders of record September 3, payable September 17. With T+1 settlement, September 2 buyers should have been holders of record September 3. That is why it screened.
Around the dividend is a proxy fight. Doug Bergeron, about a 5% holder, nominated a six-person slate aimed at longtime chairman and CEO Farooq Kathwari. Bergeron called the special a deflection. The company framed it as another chapter in a decade of cash returns.
How to treat it. A $3 special on a $25 stock is a cash event. The share price usually drops by about the dividend on the ex-date. Trading that as breakout strength is a category error. After the stock goes ex, you own a sub-$600 million furniture retailer with shrinking sales, mid-single-digit to high-single-digit operating margins, and a contested board. That can work as an event. It is a poor momentum compounder.
Comments
Post a Comment